BioSpace News Archive

With annual heat-related deaths projected to increase 370 percent by 2050, rising temperatures and extreme heat events pose a significant threat to humans.

Relmada Therapeutics, Inc. today announced the publication of REL-1017 clinical data from the Reliance I Study in the peer-reviewed journal, The Journal of Clinical Psychiatry.

Kriya Therapeutics, Inc., a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, announced the appointment of Katherine Eade to the position of Chief Legal Officer.

Alira Health, a global advisory and clinical research firm, announced today its collaboration with the Scottsdale Research Institute (SRI) to provide comprehensive regulatory and clinical support with the goal to bring clinical research of psilocybin to the State of Arizona.

Alveo Technologies, Inc., a leader in molecular sensing and diagnostics with its proprietary technology platform, announced the results of rigorous testing that demonstrate the ruggedness of its portable molecular testing platform.

Hangzhou Qihan Biotech Co., Ltd. announced its groundbreaking research titled “Testing Multiplexed anti-ASFV CRISPR-Cas9 in Reducing African Swine Fever Virus” in Microbiology Spectrum, an academic journal of the American Society for Microbiology.

Ascentage Pharma announced that it has released updated data of the Bcl-2 inhibitor lisaftoclax, one of the company’s key drug candidates, combined with novel therapeutic regimens in patients with relapsed/refractory multiple myeloma or immunoglobulin light-chain amyloidosis, in a poster presentation at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.

Santhera Pharmaceuticals announces that it has entered into committed financing arrangements that, when consummated, will provide Santhera with gross funding totaling approximately CHF 69 million to drive growth, repay maturing bonds and extend cash runway through to the first half of 2026, at which point Santhera expects to be cash flow break-even.

Nxera Pharma, announces the publication of its Annual Report and its Environment, Social & Governance Report for the year ended 31 December 2023.

China Medical System Holdings Limited is pleased to announce that on 11 June 2024, the New Drug Application of the Group’s innovative drug methylthioninium chloride enteric-coated sustained-release tablets has been approved by the National Medical Products Administration of China.